Nemvaleukin alfa

Trump's deregulatory policies and favorable economic trends could boost growth. Raymond James highlights Mural Oncology (MURA) and Disc Medicine (IRON) as stocks with significant upside potential, both with Strong Buy ratings.

Neoadjuvant nivolumab with or without ipilimumab induced immune activation in early TNBC, achieving pathologic complete responses. Cetuximab improved 2-year disease-free survival in advanced head and neck cancer. Subcutaneous pembrolizumab with berahyaluronidase alfa plus chemotherapy was noninferior to intravenous pembrolizumab. Former Celgene shareholders filed a $6.7 billion lawsuit against Bristol Myers Squibb. The BMJ retracted and updated an article on weight loss and cancer. Buxton Helmsley urged a Senate committee to investigate alleged FDA data fraud. Preoperative chemotherapy followed by surgery and radiotherapy led to a 100% clinical benefit rate in rare head and neck squamous cell carcinoma. The FDA updated fludarabine phosphate labeling. The American Lung Association highlighted improved 5-year lung cancer survival. Overdiagnosis may contribute to rising pancreatic cancer rates in young adults. History of endometriosis or uterine fibroids increased risk of premature death due to gynecologic cancers. Modified antioxidant therapy reduced chronic pain in cancer patients. Nemvaleukin alfa plus pembrolizumab achieved durable responses in several solid tumors.

Mural Oncology reports financial results for Q3 2024, updates on late-stage trials of nemvaleukin alfa, and plans for IL-18 and IL-12 programs, with data readouts expected in 2025.

Mural Oncology progresses in late-stage trials for nemvaleukin alfa, expecting data readouts in 2025 for ovarian cancer and mucosal melanoma. Plans to nominate IL-18 and IL-12 program candidates by end of 2024, with IND submission for IL-18 in Q4 2025. Cash runway projected into Q4 2025.

Mural Oncology focuses on innovating cancer care through cytokine-based immunotherapies, aiming to treat a wide range of cancers, including those resistant to current treatments. Their pipeline includes Nemvaleukin Alfa, an IL-2 variant, undergoing trials for various cancers. They emphasize the importance of clinical trials and the impact of their work on patients' lives.